Metastatic renal cell carcinoma (RCC) has been a difficult disease to treat historically with minimal response to cytotoxic chemotherapy and high mortality rates. Immunotherapy had been used in RCC with only limited success such as with high-dose interleukin 2 (IL-2), which induces approximately 5% to 10% of patients into a durable remission. 1 Treatment outcomes have improved with the introduction of vascular endothelial growth factor (VEGF)-targeted therapies in the past decade, although durable responses are still uncommon. The understanding of the interplay between the tumor and the immune system has led to the development of immune checkpoint inhibitors that are active in many solid tumors, including RCC. Nivolumab, an anti-PD-1 antibody, was recently approved as a treatment for VEGF-refractory metastatic RCC. A phase III trial compared nivolumab with everolimus and showed a significant overall survival benefit. 2 Similarly, pembrolizumab, another PD-1 inhibitor, and atezolizumab, a PD-L1 antibody, are being investigated in combination with VEGF inhibitors with encouraging initial activity and ongoing phase 3 trials. 3 As immune checkpoint inhibitors and other targeted therapies continue development in RCC, there will be an increasing need to identify patients who are more likely to benefit to inform clinical decisions.
The expression of the PD-L1 ligand on the tumor cell surface is a logical choice as a marker of response to PD-1 inhibitors. In the abovementioned phase III trial of nivolumab, the hazard ratio for overall survival benefit of nivolumab over everolimus was nearly identical regardless of PD-L1 expression. 2 The anti-PD-L1 antibody atezolizumab also failed to show an association between response and PD-L1 expression in early phase studies. 4 Several hypotheses have been forwarded to explain this lack of association. One hypothesis is that there are considerable differences in expression of PD-L1 in metastatic lesions compared with primary tumors since metastatic deposits adapt under immune selection pressures. Some studies have demonstrated this to be the case in RCC. Discordant tumor cell PD-L1 staining between primary tumors and matched metastases was observed in 20% of clear cell kidney tumors in one analysis. 5 Similarly, PD-L1 expression has been found to be weakly correlated between metastasis and primary kidney tumors in another series. 6 Another hypothesis involves the presence of other clinically significant ligands apart from PD-L1. An example of such an alternative ligand is PD-L2. 7 The role of PD-L2 and its differential expression in metastatic sites and kidney cancer primaries has not been examined previously.
Macrophage and T-cell infiltration of tumors may also be important determinants of treatment response. Macrophage polarization into tolerance-promoting (M2) and antitumor phenotypes (M1) has been described. 8 M1 and M2 macrophages are identifiable by HLA-DR and CD163 staining, respectively.
9,10 T-cell subtypes involved in the tumor-immune system interaction include the regulatory and cytotoxic T cells. Regulatory T cells express FOXP3 and are active in increasing immune tolerance, resulting in muting of the immune-mediated anticancer response.
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Regulatory T cells have been shown to influence outcome to IL-2 and sunitinib therapy in metastatic RCC. 12, 13 To gain further insight into expression of markers potentially relevant to checkpoint inhibition in RCC, matched primary and metastatic RCC tumors were characterized. The availability of matched samples could provide insight into intrapatient heterogeneity regarding biomarker expression. Such heterogeneity may have several implications, including which tissue is characterized prior to treatment selection and organ-specific clinical responses.
Materials and Methods
A search was conducted of the pathology database at the Cleveland Clinic Foundation for patients with the diagnosis of clear cell carcinoma between 1995 and 2016 for which both a nephrectomy specimen and metastatic tissue (inclusive of distant lymph nodes) were available for analysis. A cohort of 50 patients was selected based on availability of an adequate quantity of tissue for analysis. Data on tumor characteristics were extracted from original pathology reports. Clinical information was available and extracted by a review of the electronic medical record (A.B.).
Tumor Characteristics and Staging
Tumor pathology from both nephrectomy and metastasectomy specimens was reexamined by an expert genitourinary pathologist (C.P.). Information was collected on nuclear grade, lymphovascular invasion, renal sinus invasion, perinephric fat invasion, and sarcomatoid and/or rhabdoid differentiation. Nuclear grade was assigned using Fuhrman criteria.
14 For samples with heterogeneity in nuclear grade, the highest nuclear grade was recorded. A TNM stage was assigned based on standard cutoffs and notations for tumor size, nodal involvement, and metastatic disease sites using information from pathology reports, as well as from a combination of imaging studies and clinical history available from patient charts after physician review (A.B.).
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Tissue Processing and Staining
Tumor specimens were cut from formalin-fixed, paraffin-embedded (FFPE) tissue blocks, and 4-μm-thick FFPE tissue sections were used for immunostaining. The tissue sections were deparaffinized in xylene and rehydrated through graded ethanol to distilled water. For FoxP3, CD3, and CD163 immunostaining, heat-induced epitope retrieval (HIER) was performed by immersing the slides in citrate buffer for 4 minutes at 120°C. Endogenous peroxidase in tissues was blocked by incubation of slides in 3% hydrogen peroxide solution prior to incubation with primary antibody. After 60 minutes of incubation with the respective primary antibody (FoxP3, clone 236A/E7, Abcam; CD3, clone CD3-12, AbD Serotec; CD163, clone 10D6, Thermo Scientific), the sections were treated with EnVision anti-mouse/ rabbit horseradish peroxidase-conjugated polymer (DAKO). The chromogenic substrate 3,3′-diaminobenzidine (DAB; DAKO) was used to localize antigen-antibody complexes. Tissue sections were counterstained with Mayer's hematoxylin (Sigma-Aldrich), cleared, and coverslipped with permanent mounting medium. For PD-1, PD-L1, and PD-L2 immunostaining, HIER was performed by immersing the slides in FLEX High pH target retrieval solution for 4 minutes at 97°C (cat. K8012; DAKO). Endogenous peroxidase in tissues was blocked by incubation of slides in 3% hydrogen peroxide solution prior to incubation with primary antibody (anti-PD-L1, clone 22C3 and anti-PD-L2, clone 3G2, Merck Research Laboratories, or anti-PD-1 clone NAT105, Cell Marque) for 60 minutes. Antigenantibody binding was visualized via application of the FLEX+ polymer system (cat. K8012; DAKO) and application of DAB chromogen (cat. K4368; DAKO). These stained slides were counterstained with hematoxylin and coverslipped for review.
Immunohistochemistry Scoring
Scoring was conducted by an experienced pathologist (L.A.), with scores incorporating prevalence of both tumor cell and nontumor cell labeling using techniques described by us previously. 16 A semiquantitative 0 to 5 scoring system was applied such that 0 = no staining; 1 = rare individuated positive cells or only very small focus within or directly adjacent to tumor tissue; 2 = infrequent small clusters of positive cells within or directly adjacent to tumor tissue; 3 = single large cluster, multiple smaller clusters, or moderately dense diffuse infiltration, within or directly adjacent to tumor tissue; 4 = single very large dense cluster, multiple large clusters, or dense diffuse infiltration; and 5 = coalescing clusters, dense infiltration throughout the tumor tissue. Presence or absence of endothelial cell expression was evaluated specifically as a separate value. ❚Image 1❚ demonstrates these patterns of staining and associated scores.
Statistical Methods
All data analysis was performed using STATA v.12 (StataCorp LP). Data extracted from charts and staining processes were compiled into a database. Exploratory data analysis was conducted to document frequencies and measures of central tendency for summary statistics. Spearman correlation coefficients were obtained between tumor pathologic characteristics and the expression of PD-1, PD-L1, and PD-L2, as well as CD163, CD3, and FOXP3. Bonferroni corrections were made for multiple pairwise comparisons. A P value (two-sided) less than .05 was considered statistically significant.
Results
Baseline Characteristics
Forty-eight primary and metastatic tumor pairs were suitable for analysis of baseline characteristics (two patients were excluded based on lack of complete information in the electronic medical record). Metastatic lesions examined were representative of the most common metastatic sites in RCC and included lung, lymph node, and adrenal glands ❚Table 1❚. Other sites included the gastrointestinal tract, skin, non-lymph node soft tissue, and the genitourinary tract. Eighty percent of patients had advanced disease defined by a TNM stage III and greater at the time of nephrectomy, and 88% had a Fuhrman nuclear grade of 3 or higher. Most (57%) of the metastatectomies were performed within 12 months of the original nephrectomy, and 93% were obtained within 5 years of nephrectomy.
Expression of PD-1/PD-L1 and Association With Tumor Characteristics
In primary tumors, Fuhrman nuclear grade positively correlated with both increased prevalence of PD-1 staining in lymphocytes (r = 0.37, P = .02) but not with PD-L1 expression on the tumor (r = 0.30, P = .07). Fuhrman nuclear grade positively correlated with CD163 expression (r = 0.46, P < .01), indicating increasing macrophage concentration in tumors with higher nuclear grades. TNM stage of the primary tumor also positively correlated with PD-L1 expression of the primary tumors (r = 0.38, P = .02) ❚Table 2❚.
In metastatic sites, Fuhrman nuclear grade positively correlated with both increased prevalence of PD-1 staining in lymphocytes (r = 0.45, P < .01) and with PD-L1 expression on the metastatic tumor (r = 0.38, P = .02), as well as with increasing CD163 expression (r = 0.37, P = .02). Time to metastasis, as examined in years from nephrectomy, was not associated with expression of PD-1 or PD-L1 (data not shown).
Distribution of PD-L1 and PD-L2 Staining in Primary/ Metastatic Sites
Based on immunohistochemistry (IHC) scores for PD-L1 and PD-L2 in primary tumors, 32 (64%) of 50 RCC primary tumors had no significant staining for PD-L1 or PD-L2, as defined by a semiquantitative score of 3 or more, while 13 of 50 stained for either of these two markers. Five of 50 tumors had significant scoring for both ❚Figure 1❚. Twenty-seven (54%) of 50 metastatic deposits did not significantly stain for either PD-L1 or PD-L2, while 14 of 50 stained positively for either of these ligands. Nine of 50 stained positive for both PD-L1 and PD-L2 on IHC staining. There appeared to be relatively low expression for PD-L1 and PD-L2 in lymph nodes compared with kidney, lung, and adrenal metastasis. Figure 1 presents the distribution of IHC scores for primary and metastatic sites for these markers.
Concordance in PD-1, PD-L1, and PD-L2 Staining in Primary/Metastatic Sites
Thirty-three (69%) of 48 evaluable matched pairs were concordant for expression of PD-1 (ie, both sites were "positive" for the expression of PD-1 as defined by a score of 3 or higher). However, 31% of tumor pairs were discordant in their expression of PD-1 between primary tumors vs metastatic deposits. Thirteen of 50 primary tumors and 18 of 50 metastatic tumors were positive for PD-L1 expression. Thirty-eight (78%) of 49 evaluable matched pairs were concordant for the expression of PD-L1 while 11 were discordant. Finally, 39 (80%) of 49 tumor pairs were concordant for expression of PD-L2, while 10 pairs were discordant ❚Table 3❚. 
Association of Immune Checkpoint Marker Expression Within Primary and Metastatic Tumors Based on IHC
IHC scores for PD-1 and PD-L1 in primary tumors were strongly positively related (r = 0.73, P < .001), and a similar positive correlation was observed between PD-1 IHC scores and CD3 IHC scores (r = 0.72, P < .001), confirming a PD-1-expressing infiltrating T-cell response to PD-L1-expressing tumor. PD-L1 IHC scores in the primary tumors also correlated positively with CD163 (r = 0.55, P > .001) and FOXP3 scores (r = 0.653 P < .01), suggesting that increasing PD-L1 expression leads to recruitment of M2 macrophages but also regulatory T cells. PD-L1 scores did not correlate with PD-L2 IHC scores (r = 0.22, P = 1) in the primary tumors. In metastatic tumors, IHC scores for PD-1 and PD-L1 were strongly related (r = 0.67, P < .001) as well as CD3 (r = 0.72, P < .001), confirming a similar PD-1-expressing T-cell response to PD-L1-expressing tumors. In contrast to primary tumors, PD-L1 scores correlated with PD-L2 scores in metastatic tumors (r = 0.62, P < .01) ❚Table 4❚ and ❚Table 5❚. ❚Image 1❚ Immunohistochemical staining profile: renal primary vs metastases. A, Specimen 33: PD-L1 immunohistochemistry (IHC) primary tumor demonstrates a prominent marginal pattern with predominantly nontumor staining. IHC score assigned to this specimen was 3.5 (moderate to high). B, Specimen 33: PD-L1 IHC metastasis (lymph node) demonstrates strong staining in both tumor as well as infiltrating immune cells. Staining score assigned to this specimen was 5 (very high). C, Specimen 33: PD-1 IHC primary tumor demonstrates a heterogeneous distribution with a predominantly marginal pattern. IHC score assigned to this specimen was 3.5 (moderate to high). D, Specimen 33: PD-1 IHC metastasis (lymph node) demonstrates positivity in predominantly tumor cells. IHC score assigned to this specimen was 4 (high).
Discussion
Despite exploration in clinical trials, PD-L1 expression has not been a reliable marker for response to checkpoint inhibition therapy in patients with RCC. This is somewhat in contrast to other tumor types such as non-small cell lung cancer. We investigated if a discordance in the expression of PD-L1 immune checkpoint protein and an analogous ligand, PD-L2, exists in renal tumor primaries vs metastatic sites. Our study detected that a large minority of patients have clinically significant discordance in the expression of these immune checkpoint proteins, including PD-L2. This implies that the traditional assessment of PD-L1 positivity of only the primary tumor may not comprehensively address the spectrum of expression throughout tumor sites.
Another possibility for the heterogeneity of response with PD-L1 expression may be a variation in ascribing ❚Image 1❚ (cont) E, Specimen 33: PD-L2 IHC primary tumor demonstrates no faint to scattered staining across tumor and infiltrating immune cells. IHC score assigned to this specimen was 1 (rare to trace). F, Specimen 33: PD-L2 IHC metastasis (lymph node) demonstrates positivity across tumor and infiltrating cells showing a discordance between primary tumor and metastatic site. IHC score assigned to this specimen was 4 (high). (All images ×20.)
clinically significant IHC staining for immune checkpoint proteins, which vary between and within tumor types and is an evolving concept. In the current study, 74% patients expressed PD-L1 at some quantifiable level in the primary sites, and 82% expressed any PD-L1 in metastatic deposits. In contrast, only one-fourth of primary and metastatic kidney cancer specimens express a "clinically significant" degree of PD-1, PD-L1, or PD-L2, similar to the reported prevalence of PD-L1 in other studies, 2 implying that most patients have some PD-L1 expression, even though it is not considered clinically relevant.
Another finding of this study is a positive correlation of PD-L2 expression with PD-1 and PD-L1 in metastatic tumors compared with primary tumors. This phenomenon is not well reported and is hypothesis generating. PD-L2 has overlapping roles with PD-L1 and has not been examined prospectively in the clinical trials as a predictive marker. Some other proposed predictors of increased PD-L1 expression in tumor-infiltrating cells have been a higher nuclear grade, higher TNM stage, or sarcomatoid differentiation. 5, 17 In our study, an increasing nuclear grade was associated with increased expression of PD-1 and PD-L1 in primary tumors and metastatic sites, consistent with previous data. However, we did not find the TNM stage or sarcomatoid differentiation to be significant predictors of PD-L1 expression. In the absence of readily available techniques to ascertain PD-L1 expression in metastatic sites, a high nuclear grade could provide additional information and merits investigation as a marker of response to immune therapy. Our analysis has several limitations. Because of the small sample size and multiple comparisons, the strength of observed associations is limited. Also, our analysis relies on original historical pathology review for assessment of tumor characteristics and evaluation by a single pathologist for assessment of semiquantitative scoring. The study was also designed as a correlative study to examine if discordance in immune markers exist, but not its prognostic role, since survival data on these patients were not mature and would be subject to the biases inherent of a retrospective analysis should they have been analyzed. These results provide a scientific rationale to analyze immune checkpoint protein expression in metastatic sites along with primary tumors, as well as the role of PD-L2 in conjunction with PD-L1 in future prospective trials. Our study characterizes expression of immune markers potentially relevant to response to checkpoint inhibition in metastatic RCC. Additional analysis on a larger number of samples is needed to validate these findings. Discrepancies in immune checkpoint proteins between matched primary and metastatic tumors may have some clinically significant implications and should be examined further. b Statistically significant at corrected P = .05.
